Loading...
XNASPHIO
Market cap2mUSD
Dec 24, Last price  
2.07USD
1D
-7.17%
1Q
-38.21%
Jan 2017
-100.00%
IPO
-100.00%
Name

Phio Pharmaceuticals Corp

Chart & Performance

D1W1MN
XNAS:PHIO chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
85.07%
Rev. gr., 5y
-7.79%
Revenues
0k
097,000399,00071,00034,00019,00015,000138,00021,0000000
Net income
-11m
L-4.24%
-10,219,000-12,880,000-20,925,000-8,800,000-10,223,000-8,994,000-12,452,000-7,360,000-8,841,000-8,794,000-13,212,000-11,305,000-10,826,000
CFO
-11m
L-11.38%
-9,989,000-5,062,000-6,311,000-7,758,000-7,317,000-7,760,000-9,514,000-7,520,000-8,645,000-8,802,000-11,858,000-12,129,000-10,749,000
Earnings
May 07, 2025

Profile

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
URL
https://phiopharma.com/
IPO date
May 10, 2012
Employees
9
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
16,952
11,655
13,703
Unusual Expense (Income)
NOPBT
(16,952)
(11,655)
(13,703)
NOPBT Margin
Operating Taxes
(175)
(75)
Tax Rate
NOPAT
(16,952)
(11,480)
(13,628)
Net income
(10,826)
-4.24%
(11,305)
-14.43%
(13,212)
50.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,439
2
19,577
BB yield
-469.78%
0.00%
-16.95%
Debt
Debt current
70
135
125
Long-term debt
35
340
465
Deferred revenue
Other long-term liabilities
2
Net debt
(8,385)
(11,306)
(23,467)
Cash flow
Cash from operating activities
(10,749)
(12,129)
(11,858)
CAPEX
(5)
(121)
(51)
Cash from investing activities
(5)
(121)
(51)
Cash from financing activities
7,413
(26)
21,722
FCF
(16,647)
(11,408)
(13,487)
Balance
Cash
8,490
11,781
24,057
Long term investments
Excess cash
8,490
11,781
24,057
Stockholders' equity
(139,206)
(128,378)
(116,899)
Invested Capital
147,006
139,523
139,126
ROIC
ROCE
EV
Common stock shares outstanding
232
1,137
1,069
Price
6.84
-82.97%
40.18
-62.80%
108.00
-62.83%
Market cap
1,584
-96.53%
45,663
-60.46%
115,477
3.98%
EV
(6,801)
34,359
92,010
EBITDA
(16,768)
(11,462)
(13,628)
EV/EBITDA
0.41
Interest
175
9
Interest/NOPBT